ReviewThe Journal of dermatology2026
Nodular Scleroderma in a Patient With Anti-RNA Polymerase III-Antibody Positive Systemic Sclerosis: A Case Report and Literature Review.
Review in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nodular scleroderma (NS) is a rare manifestation of systemic sclerosis (SSc) that can clinically resemble keloids, often leading to diagnostic difficulty. Herein we report a case of a 76-year-old woman with anti-RNA polymerase III antibody-positive SSc who developed progressive erythematous, pruritic, keloid-like plaques 3 months after rituximab therapy. Histopathology showed thickened collagen bundles extending from the superficial to mid-dermis, increased fibroblasts, mucin deposition, and reduced elastic fibers without the hyalinized collagen characteristic of keloids, confirming NS. To date, NS associated with anti-RNA polymerase III antibody-positive SSc has not been reported. The patient was treated with topical PUVA, resulting in reduction of pruritus and softening of nodular lesions. Review of Japanese and international cases indicates that NS commonly arises during active SSc, often in areas of mechanical stress, and shows variable therapeutic response. This case expands the serological spectrum of NS and supports PUVA as a therapeutic option for symptomatic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.